English Deutsch 中文
  • Innovative Solutions
  • Expert Support and Knowledge
  • Reliable Cooperation
Menu Deutsch 中文

Amarin and Eddingpharm Announce Agreement to Develop and Commercialize Vascepa(R) (icosapent ethyl) in China

Feb. 26, 2015

February 26, 2015. Amarin Corporation  and Eddingpharm have entered into an exclusive agreement for Eddingpharm to develop and commercialize Vascepa® (icosapent ethyl) in China, the Hong Kong and Macao Special Administrative Regions and Taiwan. 

Under the agreement, Eddingpharm will be responsible for development and commercialization activities. Amarin will provide development assistance supply the finished product. Terms of the agreement include up-front and milestone payments to Amarin of up to $169.0 million, including a non-refundable $15.0 million up-front payment and development, regulatory and sales-based milestone payments of up to an additional $154million. Eddingpharm will also pay Amarin royalties on net sales of Vascepa. Amarin will supply the product to Eddingpharm under negotiated supply terms.